All GLP-1 medications from licensed 503A compounding pharmacies Browse Products

Semaglutide Results After 2 Years: What to Expect

What do semaglutide results after 2 years look like? Long-term STEP 5 data, sustained weight loss outcomes, and strategies for maintaining your progress.

By Dr. Rachel Nguyen, DO|Reviewed by Dr. David Kim, MD, FACE||

Medically Reviewed

Written by Dr. Rachel Nguyen, DO · Reviewed by Dr. David Kim, MD, FACE

Semaglutide Results After 2 Years: What to Expect custom 2026 header image for GLP-1 Weight Loss
Custom header image for Semaglutide Results After 2 Years: What to Expect, GLP-1 Weight Loss, and better treatment decision-making.
In This Article

This article is part of our GLP-1 Weight Loss collection. See also: Provider Comparisons | Peptide Guides

Search and AI answer brief

Practical answer: Semaglutide Results After 2 Years: What to Expect

What do semaglutide results after 2 years look like? Long-term STEP 5 data, sustained weight loss outcomes, and strategies for maintaining your progress.

Short answer

What do semaglutide results after 2 years look like? Long-term STEP 5 data, sustained weight loss outcomes, and strategies for maintaining your progress.

Search intent

This page answers a specific GLP-1 Weight Loss question rather than a generic overview.

What to verify

semaglutide, tirzepatide, retatrutide, cash price and coverage terms

How to use it

Use this information to prepare sharper questions for a licensed provider.

Key Takeaway

What do semaglutide results after 2 years look like? Long-term STEP 5 data, sustained weight loss outcomes, and strategies for maintaining your progress.

Two years on semaglutide is genuinely long-term treatment, and we now have strong clinical data to show what semaglutide results after 2 years look like. The STEP 5 trial was specifically designed to answer this question, and the findings are encouraging for patients committed to sustained weight management.

The Two-Year Data: STEP 5 Results

STEP 5 was a 104-week (2-year) randomized controlled trial with 304 participants taking semaglutide 2.4 mg weekly versus placebo:

  • Average weight loss at 104 weeks: 15.2% of body weight on semaglutide versus 2.6% on placebo .
  • Absolute weight loss: Approximately 35 pounds from an average starting weight of 233 pounds.
  • Responder rates: 77% of participants lost at least 5% of body weight, 54% lost at least 10%, and 36% lost at least 15%.
  • Weight trajectory: Maximum weight loss was achieved around weeks 60 to 68 (approximately 15 months), after which weight stabilized with a very slight upward trend through week 104.

The key takeaway is that semaglutide maintains the vast majority of its weight loss benefit through two full years of treatment, with minimal weight regain during the second year.

Two-Year Timeline

  • Months 1 to 4 (titration): Dose escalation from 0.25 mg to 2.4 mg. Weight loss of 5 to 10 pounds. Body adaptation and GI side effects most prominent.
  • Months 5 to 10 (peak loss): Fastest weight loss phase. Cumulative loss of 20 to 32 pounds. Metabolic improvements become significant on lab work.
  • Months 11 to 15 (maximum weight loss): Weight loss peaks and begins to plateau. Cumulative loss of 30 to 38 pounds. The body establishes a new metabolic equilibrium.
  • Months 16 to 20 (stabilization): Weight is relatively stable, with fluctuations of 2 to 4 pounds. The medication prevents the regain that would otherwise occur. Focus shifts entirely to maintenance.
  • Months 21 to 24 (sustained maintenance): Weight remains stable within a few pounds of the maximum loss achieved. Health benefits continue to accrue. Total sustained loss of 28 to 38+ pounds.

Health Benefits Sustained at Two Years

The STEP 5 and SELECT trials confirm that semaglutide's health benefits extend well beyond weight:

Check your GLP-1 eligibility

Use our free BMI Calculator to see if you may qualify for provider-reviewed GLP-1 therapy.

Try the BMI Calculator →
GLP-1 Weight Loss Results by Medication Mean Body Weight Loss (%) 0 6 12 18 24 22 15 8 24 Tirzepatide Semaglutide Liraglutide Retatrutide Based on published STEP and SURMOUNT trial data
GLP-1 Weight Loss Results by Medication. Based on published STEP and SURMOUNT trial data.
View data table
Bar chart showing glp-1 weight loss results by medication: Tirzepatide (22), Semaglutide (15), Liraglutide (8), Retatrutide (24)
CategoryMean Body Weight Loss (%)Detail
Tirzepatide22~22% body weight at 72 wks
Semaglutide15~15% body weight at 68 wks
Liraglutide8~8% body weight at 56 wks
Retatrutide24~24% in Phase 2 trial
Illustration for Semaglutide Results After 2 Years: What to Expect
  • Cardiovascular protection: The SELECT trial[2] (median follow-up 40 months) showed a 20% reduction in heart attack, stroke, and cardiovascular[2] death . By 2 years, patients are firmly within the protective window.
  • Blood sugar control: A1C improvements seen at 6 to 12 months are sustained through 2 years in patients with prediabetes or type 2 diabetes.
  • Blood pressure: Systolic blood pressure reductions of 3 to 6 mmHg persist at 2 years.
  • Cholesterol: Triglyceride reductions of 15% to 25% and modest LDL improvements continue.
  • Kidney function: The FLOW trial demonstrated a 24% reduction in kidney disease progression with semaglutide .
  • Inflammatory markers: CRP and other markers of systemic inflammation remain improved at 2 years.

What Happens in Year Two

The second year on semaglutide is fundamentally different from the first:

  • Weight stability, not weight loss: Most patients are no longer actively losing weight. This is normal and expected. The medication is now maintaining your lower weight against your body's natural drive to regain.
  • Side effects are minimal: By year two, fewer than 5% of patients report any GI symptoms. The body has fully adapted to the medication.
  • Lifestyle habits are established: Two years of healthier eating and activity patterns create lasting behavior changes that support weight maintenance.
  • Psychological adjustment: Many patients fully embrace their new body and relationship with food during year two. Some, however, experience body image challenges that benefit from professional support.

Should You Continue Beyond 2 Years?

This is one of the most common questions at the 2-year mark. The evidence strongly favors continuation for most patients: For a complete cost breakdown, see our cheapest GLP-1 without insurance.

  • The STEP 1[3] extension data showed that stopping semaglutide led to regain of approximately two-thirds of lost weight within one year .
  • The SELECT trial followed patients for up to 5 years, demonstrating ongoing safety and cardiovascular benefit with continued treatment .
  • Obesity is a chronic condition. Just as patients continue blood pressure or cholesterol medications long-term, ongoing GLP-1 therapy maintains the metabolic benefits achieved.

Some patients and providers explore dose reduction (for example, from 2.4 mg to 1.7 mg or 1.0 mg) as a maintenance strategy. Results vary, and any change should be gradual and monitored .

Frequently Asked Questions

Do people regain weight in the second year on semaglutide?

A small amount of weight regain (1% to 2% of body weight) is common during the second year as the body fully adapts to its new weight. This is minimal compared to the 10% to 15% total loss and doesn't indicate medication failure .

Are there long-term risks of taking semaglutide for 2 years?

Clinical trial data through 2 years and real-world experience through 5+ years haven't revealed any major new safety concerns. The most important risk factor is gallbladder disease, which is related to the weight loss itself rather than the medication. Regular monitoring remains important .

Can I switch medications after 2 years on semaglutide?

Yes. If you want to try tirzepatide for additional weight loss or different metabolic benefits, your provider can guide a transition. Some patients alternate between medication classes over time based on their evolving needs.

What labs should I check at the 2-year mark?

Thorough panel: A1C, fasting glucose, complete lipid panel, liver enzymes (ALT, AST), kidney function (creatinine, eGFR, UACR), thyroid panel, vitamin B12, vitamin D, iron studies, and CBC. Compare against baseline and 1-year values to track trends.

There's no maximum duration specified in the prescribing information. Semaglutide is intended for chronic use, similar to medications for high blood pressure or high cholesterol. Treatment duration should be determined collaboratively with your provider based on your individual health profile.

Medical References

  1. Garvey WT, Batterham RL, Bhatt DL, et al. Two-year effects of semaglutide in adults with overweight or obesity (STEP 5). Nat Med. 2022;28(10):2083-2091. [PubMed | ClinicalTrials.gov | DOI]
  2. Lincoff AM, Brown-Frandsen K, Colhoun HM, et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. N Engl J Med. 2023;389(24):2221-2232. [PubMed | ClinicalTrials.gov | DOI]
  3. Wilding JPH, Batterham RL, Calanna S, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. N Engl J Med. 2021;384(11):989-1002. [PubMed | ClinicalTrials.gov | DOI]

Plan Your Next Two Years

Two years on semaglutide represents a substantial health transformation. The clinical evidence supports continued treatment for maintaining your results and protecting your cardiovascular and metabolic health. FormBlends provides ongoing clinical support to ensure your treatment remains personalized and effective.

Connect with a licensed provider to review your 2-year results and plan your next phase.

Research Snapshot

Provider comparison
Page type
Provider comparison
FormBlends review
Last reviewed
2026-04-01
FormBlends review
Retatrutide evidence source
Official source
Semaglutide evidence source
Official source
Tirzepatide evidence source
Official source
Before you act
Check the current prescribing information, regulatory status, and trial source before treating an investigational or newly approved medication as interchangeable with an established therapy.
Check before ordering

Regulatory status, labels, trial records, and sponsor updates can change quickly for obesity-drug pipeline pages. This snapshot is designed to make verification easier, not to replace checking the official source before making a medical or purchase decision. Last page review: 2026-04-01.

Evidence standard

How this page was source-checked

Editorial policy

FormBlends does not claim an individual clinician byline unless a named reviewer is available. For this page, the editorial team checks medical and regulatory claims against primary sources, clinical trials, public datasets, and regulator guidance.

PubMed evidence trail

Research sources used to frame this page

For Semaglutide Results After 2 Years: What to Expect, FormBlends checks the page topic against primary trials, systematic reviews, guidelines, and current PubMed-indexed literature where available. These citations are context, not medical advice, proof of eligibility, or a claim that every study applies to every patient.

Randomized trialSemaglutide evidence2021

Once-Weekly Semaglutide in Adults with Overweight or Obesity

Primary STEP 1 trial source for semaglutide weight-management efficacy and adverse-event context.

PubMed

Randomized trialSemaglutide evidence2021

Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance

Used for maintenance, discontinuation, and weight-regain discussions after semaglutide response.

PubMed

Randomized trialSemaglutide evidence2022

Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight

Supports head-to-head context when pages compare older and newer GLP-1 options.

PubMed

Systematic reviewGLP-1 class evidence2025

Efficacy of GLP-1 Receptor Agonists on Weight Loss, BMI, and Waist Circumference

A broad meta-analysis anchor for GLP-1 weight-loss effect and class-level comparisons.

PubMed

Systematic reviewGLP-1 class evidence2025

Discontinuing glucagon-like peptide-1 receptor agonists and body habitus

Used for pages discussing stopping therapy, weight regain, and long-term planning.

PubMed

Systematic reviewGLP-1 class evidence2025

Effect of glucagon-like peptide-1 receptor agonists and co-agonists on body composition

Supports body-composition, lean-mass, and metabolic-risk context.

PubMed

Systematic reviewObesity pharmacotherapy evidence2025

Emerging pharmacotherapies for obesity: A systematic review

Broad context for new and established obesity-drug categories.

PubMed

ReviewObesity pharmacotherapy evidence2026

Glucagon-like receptor agonists and next-generation incretin-based medications

Current review for incretin-based obesity medications and cardiometabolic effects.

PubMed

Systematic reviewObesity pharmacotherapy evidence2025

Efficacy of GLP-1 Receptor Agonists on Weight Loss, BMI, and Waist Circumference

Used as a class-level evidence anchor when no more specific citation group matches.

PubMed

GLP-1 decision path

Use this page to decide if a provider review is the right next step

Direct answer

Semaglutide Results After 2 Years: What to Expect research is most useful when it helps you compare eligibility, expected results, side effects, cost, and the supervision needed before treatment.

Evidence check

The strongest GLP-1 pages connect the practical answer to clinical trials, FDA labeling where applicable, and real access constraints.

Safety check

A licensed clinician still needs to review health history, contraindications, current medications, side effects, and dose escalation.

Next step

When the page matches your goal, continue into the FormBlends get-started flow so the intake can route you toward the right prescription review path.

FormBlends Editorial Context

Reviewed May 14, 2026

What do semaglutide results after 2 years look like? Long-term STEP 5 data, sustained weight loss outcomes, and strategies for maintaining your progress. Read "Semaglutide Results After 2 Years: What to Expect" as a GLP-1 treatment guide where medication choice, dosing, side effects, monitoring, and insurance rules can change the decision. The main job of this page is patient education and clinical context, especially where the topic touches semaglutide. Because this article has 7 major sections, scan the headings first and then use the FAQ or summary sections to pressure-test the answer. Use it to ask sharper questions of a licensed clinician, not as a substitute for personal medical advice.

  • Confirm whether the page is discussing an FDA-approved use, a compounded option, or research-only context.
  • Ask a licensed clinician how the evidence applies to your health history, medications, labs, and side-effect risk.
  • Check the latest label, trial update, pharmacy policy, or state rule when the article touches medication access.

Original tools and data

Use the FormBlends research stack

These assets are built to be useful beyond a single article: shareable data pages, calculators, provider comparisons, and safety checks that give Google and readers something original to crawl.

Editorial refresh

Practical 2026 note for Semaglutide Results After 2 Years

For this glp-1 weight loss page, the 2026 refresh focuses on semaglutide, tirzepatide, retatrutide, cash-pay pricing, safety signals, results so the article stays close to the question behind "Semaglutide Results After 2 Years".

The useful details are the practical ones: what to verify, what changes risk or cost, and which details separate Semaglutide Results After 2 Years from nearby GLP-1, peptide, hormone, or provider-comparison searches.

Readers can use the added context to bring sharper questions to a licensed provider before making a treatment, cost, or care decision.

Semaglutide Results After 2 Years custom 2026 image for glp-1 weight loss on FormBlends

Custom 2026 image for Semaglutide Results After 2 Years, glp-1 weight loss, and better treatment decision-making.

Image description: Unique image for this page covering Semaglutide Results After 2 Years, glp-1 weight loss, safety, cost, provider selection, and patient decision-making.

Medical Disclaimer: This content is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare provider before starting, stopping, or changing any medication or treatment. FormBlends articles are source-checked against medical and regulatory references, but they are not a substitute for a personal medical consultation.

Written by Dr. Rachel Nguyen, DO

Obesity Medicine Specialist. This article was researched against primary regulatory, trial, prescribing, and manufacturer sources where available. Reviewed by Dr. David Kim, MD, FACE for medical accuracy, sourcing, and patient-safety framing.

Ready to get started?

Provider-reviewed GLP-1 and peptide therapy, delivered to your door.

Start Your Consultation

Ready to Start Your Weight Loss Journey?

Get a free medical consultation with a licensed provider. Compounded GLP-1 medications starting at $99/month with free shipping.

Next Best Reads

Free Tools

Provider-informed calculators to support your weight loss journey.